Octreotide Injection

342 interactions 555 cited references
Also sold as: Bynfezia Bynfezia® Mycapssa Sandostatin Sandostatin® Sandostatin® LAR Depot
About Octreotide Injection

Octreotide immediate-release injection is used to decrease the amount of growth hormone (a natural substance) produced by people with acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) who cannot be treat… Read the full Octreotide Injection drug information page →

Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 10, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dronedarone Levoketoconazole Levomethadyl Mesoridazine Pimozide Ziprasidone
13 Contraindicated 325 Major 4 Moderate
All (342) Contraindicated (13) Major (325) Moderate (4)

Major

Octreotide Injection Mestranol Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Metformin Fortamet® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Methadone Diskets Increased risk of QT interval prolongation Details Octreotide Injection Methotrimeprazine An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Metronidazole Flagyl An increased risk of QT interval prolongation Details Octreotide Injection Midostaurin Rydapt Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Mifepristone Korlym An increased risk of QT interval prolongation Details Octreotide Injection Miglitol Glyset® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Milsaperidone An increased risk of QT interval prolongation Details Octreotide Injection Mirtazapine Mirataz Increased risk of QT interval prolongation and torsades de pointes Details Octreotide Injection Mobocertinib Exkivity An increased risk of QT interval prolongation Details Octreotide Injection Moxifloxacin Avelox Increased risk of QT interval prolongation Details Octreotide Injection Nateglinide Starlix® An increased risk of hypoglycemia and impaired glucose regulation Details Octreotide Injection Nelfinavir Viracept Increased risk of QT interval prolongation Details Octreotide Injection Neratinib Nerlynx Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Nilotinib An increased risk of QT interval prolongation Details Octreotide Injection Nizatidine Axid® Decreased octreotide bioavailability Details Octreotide Injection Nomegestrol Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Norethindrone Aygestin Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Norfloxacin An increased risk of QT interval prolongation Details Octreotide Injection Norgestimate Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Norgestrel Decreased bioavailability and decreased efficacy of combined oral contraceptives or increased breakthrough bleeding Details Octreotide Injection Nortriptyline An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Injection Ofloxacin Floxin® An increased risk of QT interval prolongation Details Octreotide Injection Olanzapine An increased risk of QT interval prolongation Details Octreotide Injection Olaparib Lynparza Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Olodaterol Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Octreotide Injection Omeprazole Gastrobim Decreased octreotide bioavailability Details Octreotide Injection Ondansetron An increased risk of QT interval prolongation Details Octreotide Injection Osilodrostat Isturisa Increased risk of QT interval prolongation Details Octreotide Injection Osimertinib Tagrisso Increased risk of QT interval prolongation Details Octreotide Injection Oxaliplatin Increased risk of QT-interval prolongation Details Octreotide Injection Oxycodone Oxaydo Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Ozanimod Additive effects on heart rate Details Octreotide Injection Paclitaxel Abraxane Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Injection Pacritinib Vonjo® An increased risk of QT interval prolongation Details Octreotide Injection Paliperidone Erzofri An increased risk of QT interval prolongation and torsade de pointes Details Octreotide Injection Panobinostat Farydak Increased risk of QT interval prolongation Details Octreotide Injection Pantoprazole Protonix Decreased octreotide bioavailability Details Octreotide Injection Paroxetine Paxil An increased risk of QT interval prolongation Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.